Singapore markets open in 6 hours 33 minutes

Kyverna Therapeutics, Inc. (KYTX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
7.45+0.18 (+2.48%)
As of 02:26PM EDT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 313.45M
Enterprise value -45.50M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)0.87
Enterprise value/revenue 3.34k
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) N/A
52-week change 3-75.85%
S&P500 52-week change 324.60%
52-week high 330.60
52-week low 36.75
50-day moving average 313.87
200-day moving average 319.94

Share statistics

Avg vol (3-month) 3568.55k
Avg vol (10-day) 31.36M
Shares outstanding 543.12M
Implied shares outstanding 643.12M
Float 822.54M
% held by insiders 110.77%
% held by institutions 181.93%
Shares short (14 Jun 2024) 43.23M
Short ratio (14 Jun 2024) 45.14
Short % of float (14 Jun 2024) 413.56%
Short % of shares outstanding (14 Jun 2024) 47.49%
Shares short (prior month 15 May 2024) 42.73M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)N/A
Return on equity (ttm)N/A

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -78.31M
Net income avi to common (ttm)-75.92M
Diluted EPS (ttm)N/A
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)369.79M
Total cash per share (mrq)8.58
Total debt (mrq)10.85M
Total debt/equity (mrq)3.01%
Current ratio (mrq)17.17
Book value per share (mrq)N/A

Cash flow statement

Operating cash flow (ttm)-66.48M
Levered free cash flow (ttm)N/A